Cargando…

Long-Term Safety from the Raltegravir Clinical Development Program

BACKGROUND: Raltegravir has demonstrated potent and durable efficacy and a favorable safety profile in 3 phase III studies in treatment-naïve and treatment-experienced patients with HIV-1 infection. This manuscript provides a review of the raltegravir safety profile using data from these and other s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Teppler, Hedy, Brown, Deborah D, Leavitt, Randi Y, Sklar, Peter, Wan, Hong, Xu, Xia, Lievano, Fabio, Lievano, Heidi P, Christopher Mast, T, Nguyen, Bach-Yen T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Science Publishers Ltd 2011
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3267161/ https://www.ncbi.nlm.nih.gov/pubmed/21198432 http://dx.doi.org/10.2174/157016211794582650

Ejemplares similares

Influence of Sex/Gender and Race on Responses to Raltegravir Combined With Tenofovir-Emtricitabine in Treatment-Naive Human Immunodeficiency Virus-1 Infected Patients: Pooled Analyses of the STARTMRK and QDMRK Studies
por: Squires, Kathleen, et al.
Publicado: (2017)

1617 Safety, Tolerability, and Antiretroviral Activity of Raltegravir in HIV-1 Infected Russian Children and Adolescents – a 24 Week Study
por: Teppler, Hedy, et al.
Publicado: (2014)

Maternal–Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing
por: Lommerse, Jos, et al.
Publicado: (2019)

A Health Literate Patient-focused Approach to the Redesign of the Raltegravir (ISENTRESS) Pediatric Kit and Instructions for Use
por: Mills, Alexander, et al.
Publicado: (2021)

Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority Trial
por: Cahn, Pedro, et al.
Publicado: (2018)

Long-term efficacy and safety of raltegravir in the management of HIV infection
por: Liedtke, Michelle D, et al.
Publicado: (2014)

[Leyes y decretos del Estado de Chiapas]
por: Liévano, Vicente

Análisis y simulación de circuitos usando PSPICE /
por: Lievano García, ALfredo
Publicado: (2003)

Cría intensiva de cerdos comerciales /
por: Liévano Reyes, Joaquín
Publicado: (1989)

Bolívar
por: Liévano Aguirre, Indalecio
Publicado: (1983)

Los grandes conflictos sociales y económicos de nuestra historia /
por: Liévano Aguirre, Indalecio
Publicado: (1974)

1050 Evaluation of syncope and related events following vaccination with quadrivalent human papillomavirus vaccine (2006-2013)
por: Lievano, Fabio, et al.
Publicado: (2014)

Derecho internacional público /
por: Gaviria Liévano, Enrique, 1939-
Publicado: (2005)

Raltegravir monohydrate
por: Yamuna, Thammarse S., et al.
Publicado: (2013)

Aprendizaje organizacional : naturaleza, evolución y perspectivas
por: Moguel Liévano, Manuel de Jesús
Publicado: (2005)

Linking Mitochondria to Synapses: New Insights for Stress-Related Neuropsychiatric Disorders
por: Jeanneteau, Freddy, et al.
Publicado: (2016)

Development and Implementation of an Online Global Pharmacovigilance Certificate Program During the COVID-19 Pandemic
por: Doan, Thao, et al.
Publicado: (2022)

Analysis of BENCHMRK 1 & 2 using PhenoSense® assay for darunavir (DRV/r) resistance and exploration of functional monotherapy with RAL vs DRV
por: Rockstroh, J, et al.
Publicado: (2010)

Estimating the drivers of urban economic complexity and their connection to economic performance
por: Gomez-Lievano, Andres, et al.
Publicado: (2021)

Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection
por: Amin, Janaki, et al.
Publicado: (2015)

HIV resistance to raltegravir
por: Clavel, François
Publicado: (2009)

Correction: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection
por: Amin, Janaki, et al.
Publicado: (2015)

High levels of polymorphisms related to raltegravir resistance among raltegravir-naïve individuals in Brazil
por: Pena, N Mantovani, et al.
Publicado: (2010)

Raltegravir for HIV-1 infected children and adolescents: efficacy, safety, and pharmacokinetics
por: Larson, Kajal B, et al.
Publicado: (2013)

Evaluation of Neural Tube Defects (NTDs) After Exposure to Raltegravir During Pregnancy
por: Shamsuddin, Hala, et al.
Publicado: (2019)

Long-term outcomes of highly experienced people with HIV undergoing salvage therapy with raltegravir
por: Patiño Escarcina, Jesús Enrique, et al.
Publicado: (2023)

Drug-drug interactions with raltegravir
por: Burger, David M
Publicado: (2009)

Raltegravir in treatment naïve patients
por: Cossarini, F, et al.
Publicado: (2009)

Raltegravir use in special populations
por: Johnson, Margaret
Publicado: (2009)

Adverse events of raltegravir and dolutegravir
por: Elzi, Luigia, et al.
Publicado: (2017)

Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations
por: Wong, Alexander, et al.
Publicado: (2019)

Prosthetic resurfacing of engaging posterior capitellar defects in recurrent posterolateral rotatory instability of the elbow
por: Rotman, Dani, et al.
Publicado: (2023)

Long-term tolerability and effectiveness of raltegravir in Japanese patients: Results from post-marketing surveillance
por: Kuroishi, Naho, et al.
Publicado: (2019)

Comparison of Illumina and 454 Deep Sequencing in Participants Failing Raltegravir-Based Antiretroviral Therapy
por: Li, Jonathan Z., et al.
Publicado: (2014)

Raltegravir in the management of HIV-infected patients
por: Stellbrink, Hans-Jürgen
Publicado: (2009)

Spectrophotometric Estimation of Raltegravir Potassium in Tablets
por: Kore, P. P., et al.
Publicado: (2014)

The Statistics of Urban Scaling and Their Connection to Zipf’s Law
por: Gomez-Lievano, Andres, et al.
Publicado: (2012)

The pharmacokinetic and safety profile of raltegravir and ribavirin, when dosed separately and together, in healthy volunteers
por: Ashby, J, et al.
Publicado: (2010)

Digital Additional Risk Minimization Measures: An Exploratory Study Using Qualitative Feedback from Healthcare Professionals and Patients Across Six Countries
por: Da Silva-Tillmann, Barbara, et al.
Publicado: (2022)

Dual imaging of dendritic spines and mitochondria in vivo reveals hotspots of plasticity and metabolic adaptation to stress
por: Dromard, Yann, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_70dib4alkort840rcq55qifndu